Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of RVX000222 for coronary plaque regression assessed by intravascular ultrasound
2010-023801-36Phase 2Completed
- Sponsor
- Resverlogix Corp.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing RVX000222 with Placebo (2 arms). Primary endpoint: Change in percent atheroma volume. Started Aug 2011; status: completed.
02
Drugs
apabetalone
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2010-023801-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023801-36.